Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
4.72M
-
Shares change
-
+4.72M
-
Total reported value, excl. options
-
$85.2M
-
Value change
-
+$85.2M
-
Number of buys
-
20
-
Price
-
$18.06
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2017
20 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2017.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.72M shares
of 46.2M outstanding shares and own 10.2% of the company stock.
Largest 10 shareholders include ProQuest Associates IV LLC (1.45M shares), FMR LLC (769K shares), WELLINGTON MANAGEMENT GROUP LLP (753K shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (425K shares), Hillhouse Capital Management, Ltd. (352K shares), PERCEPTIVE ADVISORS LLC (269K shares), JENNISON ASSOCIATES LLC (175K shares), Wildcat Capital Management, LLC (135K shares), MENORA MIVTACHIM HOLDINGS LTD. (129K shares), and Alyeska Investment Group, L.P. (50K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.